ClinicalTrials.gg
CompletedNCT00132886Updated May 3, 2012

Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure

A Phase 2 interventional study of tolvaptan in Heart Failure, Congestive, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 31 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-03.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.

Planned enrollment
5th of 19
140 · median 60
Started
2004
with 1 other
Phase 2
4 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
5 of 19
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 19 studies testing tolvaptan in Heart Failure, this one is the 5th largest by planned enrollment, is one of 2 that started in 2004, is one of 4 in phase 2, and was the 4th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing tolvaptan in Heart Failure as a file.
02

Study summary

This study will look at how a single dose of study medication (tolvaptan) versus an inactive sugar pill (placebo) effect pressures in the heart in patients with congestive heart failure. Higher than normal pressures can be related to symptoms of heart failure (shortness of breath, fatigue, etc.).

03

Conditions studied

  • Heart Failure, Congestive

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Class III or IV heart failure for at least 3 months
  • less than or equal to 40%
  • Currently being treated for heart failure with standard therapies for at least one month

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding
  • Inability to take oral medications
  • Uncontrolled hypertension, bradyarrhythmias or tachyarrhythmias
  • Hypertrophic obstructive cardiomyopathy
  • Severe obstructive pulmonary disease
  • Significant renal impairment
  • Significant uncorrected valvular or congenital heart disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
140 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in heart pressures (PCWP) at 3 to 8 hours post-dose

Secondary outcomes

  1. Change in heart function measurements (CI, SVR, PVR, RAP) at 3 to 8 hours post-dose

  2. Change in urine output and free water clearance

  3. Change from baseline in urine osmolality

  4. Cmax, tmax, and AUC 12h of tolvaptan in plasma

  5. Adverse events, vital signs and clinical labs

07

Study locations

31 sites
  • Oracle Research, A Div of the Heart Center
    Huntsville, Alabama 35801, United States
  • Merced Heart Associates
    Merced, California 95340, United States
  • Olive View-UCLA Medical Center
    Sylmar, California 91324, United States
  • Broward General Medical Center
    Ft. Lauderdale, Florida 33316, United States
  • Cardiovascular Center at Shands Jacksonville
    Jacksonville, Florida 32209, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • ACRI
    Atlanta, Georgia 30342, United States
  • Northwestern University
    Chicago, Illinois 60612, United States
  • Robert Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Loyola University of Chicago
    Maywood, Illinois 60153, United States
  • University of Iowa Health Care
    Iowa City, Iowa 52242, United States
  • Cardiologist Institute
    Slidell, Louisiana 70458, United States
  • Medical Research Institute Louisiana Heart Hospital
    Slidell, Louisiana 70458, United States
  • Primary Cardiology Associates
    Ayer, Massachusetts 01432, United States
  • U-MASS Memorial Medical Center
    Worchester, Massachusetts 01655, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Heart Consultants, PC
    Omaha, Nebraska 68122, United States
  • University of Medicine and Dentistry
    Newark, New Jersey 07103, United States
  • UNC Heart Failure Program
    Chapel Hill, North Carolina 27517, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland VA Medical Center
    Cleveland, Ohio 44106, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Guthrie Foundation
    Syre, Pennsylvania 18840, United States
  • Texas Heart Institute
    Houston, Texas 77702, United States
  • Southeast Texas Clinical Research
    Orange, Texas 77702, United States
  • Spitalul Clinic Urgenta
    Bucuresti, 014461, Romania
  • Institutul de Boli Cardiovasculare
    Bucuresti, 022322, Romania
  • Institutul de Boli Cardiovasculare"Prof. Dr. C.C. Illiescu"
    Bucuresti, Cod 022322, Romania
  • Institutul Inimii
    Judetul Cluj, Cod 400001, Romania
  • Institutul de Boli Cardiovasculare si Transplant
    Judetul Mures, Cod 540136, Romania
08

References and documents

Publications

  • Hiukka A, Westerbacka J, Leinonen ES, Watanabe H, Wiklund O, Hulten LM, Salonen JT, Tuomainen TP, Yki-Jarvinen H, Keech AC, Taskinen MR. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol. 2008 Dec 16;52(25):2190-7. doi: 10.1016/j.jacc.2008.09.049. PubMed 19095138 ↗
  • Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008 Nov 4;52(19):1540-5. doi: 10.1016/j.jacc.2008.08.013. PubMed 19007589 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2005
First posted
Aug 22, 2005
Start
Dec 2004
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Last update
May 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00132886
First posted
Aug 22, 2005
Start date
Dec 2004
Primary completion
Dec 2006
Completion
Dec 2006
Last update
May 3, 2012

Study contacts

James Udelson, MD
study chair · Cardiovascular Clinical Studies and Tufts/New England Medical Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion